Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine Is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: A pediatric oncology group study

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 331-337

  Graham, Michael L ^a,k   Shuster, Jonathan J ^b   Kamen, Barton A ^c   Land, Vita J ^d   Borowitz, Michael J ^a   Camitta, Bruce ^e   Cheo, David L ^f   Harrison, Matthew P ^f   Leventhal, Brigid G ^f   Pinkel, Donald P ^g   Pullen, D Jeanette ^h   Steuber, Phillip ⁱ   Whitehead, V Michael ^j  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d ST LOUIS CHILDREN S HOSPITAL   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g UNIVERSITY OF TEXAS   (United States)

^h UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

^j MONTREAL CHILDREN S HOSPITAL   (Canada)

^k Pediatric Oncology Group   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYTARABINE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ERYTHROCYTE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0029983047     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Avery, T. L., and Roberts, D. W. Dose-related synergism of cytarabine and methotrexate against murine leukemia L1210. Eur. J. Cancer, 10: 425-429, 1974.
2. Roberts, D. W., Peck, C., Hilliard, S., and Wingo, W. Methotrexate-induced changes in the levels of 1-β-D-arabinofuranosylcytosine triphosphate in L1210 cells Cancer Res., 39: 4048-4054, 1979
3. Edelstein, M., Vietti, T., and Valeriote, F. The enhanced cytotoxicity of combinations of 1-β-D-arabinofuranosylcytosine and methotrexate. Cancer Res., 35: 1555-1558, 1975.
4. Cadman, E., and Eiferman, F. Mechanism of synergistic cell killing when methotrexate precedes cytarabine: study of L1210 and human leukemic cells. J. Clin. Invest., 64: 788-797, 1979.
5. Zager, R. F., Frisby, S. A., and Oliverio, V. T. The effects of antibiotics and cancer chemotherapeutic agents on the cellular transport and antitumor activity of methotrexate in L1210 murine leukemia. Cancer Res., 33: 1670-1676, 1973.
6. Hoovis, M. L., and Chu, M. Y. Enhancement of the antiproliferative action of 1-β-D-arabinofuranosylcytosine by methotrexate in murine leukemic cells (L5178Y). Cancer Res., 33: 521-525, 1973.
7. Tanizawa, A., Kubota, M., Takimoto, T., Kito, T., Akiyama, Y , Kiriyama, Y., and Mikawa, H. Synergistic effect of methotrexate and 1-β-arabinofuranosylcytosine on the generation of DNA strand breaks in a human promyelocytic leukemia cell line. Leuk Res , 13: 151-156, 1989.
8. Burchenal, J H., and Dollinger, M. R. Cytarabine (NSC-63,878) in combination with 6-mercaptopurine (NSC-755), methotrexate (NSC-740), or 5-fluorouracil (NSC-19893) in L1210 mouse leukemia. Cancer Chemother. Rep., 51: 435-438, 1967.
9. Jackson, R. C., and Harkrader, R. J. Synergistic and antagonistic interactions of methotrexate and 1-β-D-arabinofuranosylcytosine in hepatoma cells: the modulating effect of purines. Biochem. Pharmacol., 30, 223-229, 1981.
10. Grindey, G. B., and Nichol, C. A. Interaction of drugs inhibiting different steps in the synthesis of DNA. Cancer Res., 32: 527-531, 1972.
11. Tattersall, M. H. N , and Harrap, K. R. Combination chemotherapy: the antagonism of methotrexate and cytarabine. Eur. J. Cancer, 9: 229-232, 1973.
12. Goz, B., Carl, P. L., and Tlsty, T. 1-β-arabinofuranoscylcytosine enhancement of resistance to several antineoplastic drugs in mammalian tissue culture cells Mol. Pharmacol., 36: 360-365, 1989.
13. Nitschke, R , Komp, D. M., Morgan, S. K., Starling, K. A., and Vietti, T. J. Toxicity study of cytosine arabinosde and methotrexate in the maintenance of childhood leukemia, a Southwest Oncology Group study. J. Clin. Pharmacol., 18: 131-135, 1978.
14. Rivera, G , Murphy, S. B., Aur, R. J. A., Vervosa, M. S., Dahl, G. V., and Mauer, A. M. Recurrent childhood lymphocytic leukemia, clinical and cytokinetic studies of cytosine arabinosde and methotrexate for maintenance of second hematologic remission. Cancer (Phila.), 42: 2521-2528, 1978.
15. Krance, R. A., Newman, E. M., Ravindranath, Y., Harris, M. B., Brecher, M., Wimmer, R., Shuster, J. J., Land, V. J., Pullen, J., Crist, W., and Pinkel, D. A pilot study of intermediate-dose methotrexate and cytarabine, "spread out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia: a Pediatric Oncology Group study. Cancer (Phila.), 67: 550-556, 1991.
16. Newman, E. M., Villacorte, D. G., Testi, A. M., Krance, R. A., Harris, M. B., Ravindranath, Y., and Pinkel, D. Biochemical interactions between methotrexate and 1-β-D-arabinofuranosylcytosine in hematopoetic cells of children: a Pediatric Oncology Group study. Cancer Chemother. Pharmacol., 27: 60-66, 1990.
17. Craft, A. W., Rankin, A. W., and Aherne, W. Methotrexate absorption in children with acute lymphoblastic leukemia. Cancer Treat. Rep. 65(Suppl. 1): 77-81, 1980.
18. Pearson, A. D. J., Amineddine, H. A., Yule, M., Mills, S., Long, D. R., Craft, A. W., and Chessells, J. M. The influence of serum methotrexate concentration and drug dosage on outcome in childhood acute lymphoblastic leukaemia, Br. J. Cancer. 64: 1969-1973, 1991.
19. Evans, W. E., Crom, W. R., Abromowitch, M., Dodge, R., Look, A. T., Bowman, W. P., Georges, S. L., and Pui, C-H. Clinical pharmacodynamics of high-dose methotrexate in acute lymphoblastic leukemia - identification of a relation between concentration and effect. N. Engl. J. Med., 314: 471-477, 1986.
20. Evans, W. E , Crom, W. R., Schell, M. J., Kalwinski, D. K., and Rivera, G. K. Reappraisal of methotrexate clearance as a prognostic factor in childhood acute lymphocytic leukemia. Proc. Am. Assoc. Cancer Res., 30: 241, 1989.
21. Borsi, J. D., and Moe, P. J. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer (Phila.), 60. 3020-3024, 1987.
22. Camitta, B., Mahoney, D., Leventhal, B., Lauer, S. J., Shuster, J. J., Adair, S., Civin, C., Munoz, L., Steuber, P., and Strother, D. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: a Pediatric Oncology Group study. J. Clin. Oncol., 12: 1383-1389, 1994.
23. de Costa, M., and Iqbal, M. The transport and accumulation of methotrexate in human erythrocytes. Cancer (Phila.), 48: 2427-2432, 1981.
24. Lena, N., Imbert, A. M., Brunet, P., Cano, J. P , and Carcassonne, Y. Kinetics of methotrexate and its metabolites in red blood cells. Cancer Drug. Delivery, 4: 119-127, 1987.
25. Schmiegelow, K., Schroder, H., Pulczynska, M. K., and Hejl, M. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes. Cancer Chemother. Pharmacol., 25: 65-69, 1989.
26. Graham, M., Camitta, B., Lauer, S., Leventhal, B., Casper, J., Civin, C., Cheo, D., and Zuharuk, M. Methotrexate (MTX) pharmacology in patients receiving intensive MTX/6-mercaptopurine (6-MP) consolidation for acute lymphocytic leukemia (ALL): a Pediatric Oncology Group study. Proc. Am. Assoc. Cancer Res., 29: 226, 1988.
27. Kamen, B. A., Hockenberg, J. S., Turo, K., and Whitehead, V. M. Methotrexate and folate content of erythrocytes in patients receiving oral vs. intramuscular therapy with methotrexate. J. Pediatr., 104: 131-133, 1984.
28. Graham, M., Winick, N., Camitta, B., and Kamen, B. A. Equivalence of methotrexate concentration in erythrocytes between IV and oral dosing regimens. Cancer Res. Ther. Control, 3: 53-55, 1992.
29. Kamen, B. A., Nylen, P. A., Camitta, B. M., and Bertino, J. R. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity of the drug. Br. J. Haematol., 49: 355-360, 1981.
30. Schroder, H., Clausen, N., Ostergaarde, E., and Pressler, T. Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment. Cancer Chemother. Pharmacol., 16: 190-193, 1986.
31. Graham, M. L., Shuster, J. J., Kamen, G. A., Cheo, D. L., Harrison, M. P., Leventhal, B. G., Pullen, D. J., and Whitehead, V. M. Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study. Cancer Chemother. Pharmacol., 31: 217-222, 1992.
32. Schroder, H. In vivo methotrexate kinetics and metabolism in human hematopoetic cells: clinical significance of methotrexate concentration in erythrocytes. Dan. Med. Bull, 37: 22-40, 1990.
33. Trueworthy, R., Shuster, J., Look, T., Crist, W., Borowitz, M. Carroll, A., Frankel, L., Harris, M., Wagner, H., and Haggard, M. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J. Clin. Oncol., 10: 606-613, 1992.
34. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
35. Peto, R , Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, L., Peto, K., and Smith, P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.